Abstract:Immunization through repeated direct venous inoculation of Plasmodium falciparum (Pf) sporozoites (PfSPZ) under chloroquine chemoprophylaxis, using the PfSPZ Chemoprophylaxis Vaccine (PfSPZ-CVac), induces high-level protection against controlled human malaria infection (CHMI). Humoral and cellular immunity contribute to vaccine efficacy but only limited information about the implicated Pf-specific antigens is available. Here, we examined Pf-specific antibody profiles, measured by protein arrays representing the full Pf proteome, of 40 placebo- and PfSPZ-immunized malaria-naïve volunteers from an earlier published PfSPZ-CVac dose-escalation trial. For this purpose, we both utilized and adapted supervised machine learning methods to identify predictive antibody profiles at two different time points: after immunization and before CHMI. We developed an adapted multitask support vector machine (SVM) approach and compared it to standard methods, i.e. single-task SVM, regularized logistic regression and random forests. Our results show, that the multitask SVM approach improved the classification performance to discriminate the protection status based on the underlying antibody-profiles while combining time- and dose-dependent data in the prediction model. Additionally, we developed the new f E ature di S tance ex P lainabilit Y (ESPY) method to quantify the impact of single antigens on the non-linear multitask SVM model and make it more interpretable. In conclusion, our multitask SVM model outperforms the studied standard approaches in regard of classification performance. Moreover, with our new explanation method ESPY, we were able to interpret the impact of Pf-specific antigen antibody responses that predict sterile protective immunity against CHMI after immunization. The identified Pf-specific antigens may contribute to a better understanding of immunity against human malaria and may foster vaccine development. Developing an effective malaria vaccine is challenging. Malaria is a life-threatening disease caused by the plasmodium parasite, which has a complex multi-stage life-cycle and expresses several thousand proteins in a highly coordinated manner. To date, our understanding of the immune mechanisms mediating protection against Plasmodium falciparum (Pf) is incomplete. Proteome microarrays have been used earlier by our clinical collaboration partners to identify Pf-specific antibody profiles of malaria-naïve volunteers during immunization with attenuated Pf sporozoites (PfSPZ). We reused this data to compare the ability of three supervised machine learning methods to identify predictive antibody profiles after immunization and before controlled human malaria infection (CHMI). We adapted a multitask support vector machine (SVM) approach to analyze time-dependent Pf-induced antibody profiles from several time points in a single prediction model. Our multitask SVM approach outperforms the studied standard approaches in classification performance. Additionally, we developed a new explanation method, named f E ature di S tance ex P lainabilit Y (ESPY), to interpret the impact of Pf-specific antigens. We applied ESPY on the multitask SVM model and identified diverse Pf-specific antigen sets after immunization and before CHMI. Furthermore, we showed that the identified Pf-induced antibody profiles vary among protected and non-protected individuals who had been exposed to different doses of PfSPZ.

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy

Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria

Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults

PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

IMRAS-Immunization with Radiation-Attenuated Plasmodium Falciparum Sporozoites by Mosquito Bite: Cellular Immunity to Sporozoites, CSP, AMA1, TRAP and CelTOS

Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults

A Human Monoclonal Antibody Prevents Malaria Infection by Targeting a New Site of Vulnerability on the Parasite (vol 24, Pg 408, 2018)

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein

Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection

CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Machine learning prediction of malaria vaccine efficacy based on antibody profiles

Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses against Plasmodium liver infection

In vitro production of infectious Plasmodium falciparum sporozoites